市場調査レポート
商品コード
1422819
PEG化タンパク質市場レポート:製品タイプ、タンパク質タイプ、用途、エンドユーザー、地域別2024-2032PEGylated Proteins Market Report by Product, Protein Type, Application, End User, and Region 2024-2032 |
● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。 詳細はお問い合わせください。
PEG化タンパク質市場レポート:製品タイプ、タンパク質タイプ、用途、エンドユーザー、地域別2024-2032 |
出版日: 2024年01月30日
発行: IMARC
ページ情報: 英文 144 Pages
納期: 2~3営業日
|
世界のPEG化タンパク質市場規模は2023年に13億米ドルに達しました。今後、IMARC Groupは、市場が2032年までに28億米ドルに達し、2024年から2032年の間に8.87%の成長率(CAGR)を示すと予測しています。慢性疾患の有病率の増加、がん治療における製品の利用拡大、PEG化タンパク質の製品承認数の増加は、市場を牽引する主な要因のいくつかです。
PEG化タンパク質は、ポリエチレングリコール(PEG)との共有結合によって修飾された生体分子です。PEG化は、生体分子のコンフォメーション、静電結合、疎水性などの物理的・化学的特性を変化させることにより、医薬品の薬物動態学的挙動を改善する技術です。PEG化タンパク質は、ワクチン、ホルモン補充療法、遺伝性疾患、貧血、血液凝固障害などの治療用途に広く使用されています。また、腎臓病、多発性硬化症、血友病、がんを含む様々な病気の治療薬にも使用されています。PEG化タンパク質は、半減期の延長、安定性、溶解性の向上、タンパク質分解保護、腎排泄、免疫原性、毒性の低減、ドラッグデリバリーの有効性の向上に役立ちます。これに加えて、PEG化タンパク質は無毒性、水溶性、親水性、非抗原性、非免疫原性です。
世界中で腎臓病、自己免疫疾患、遺伝性疾患、肝炎、関節リウマチなどの慢性疾患の有病率が上昇していることが、市場成長を促進する主な要因の一つです。PEG化タンパク質は、炎症の治療、細胞への修正遺伝子の送達、血栓の予防、成長ホルモンの送達、慢性腎臓病の進行予防などに広く使用されています。これに伴い、化学療法薬をがん細胞に直接送達し、健康な細胞への副作用を軽減するために、がん治療において広く製品が利用されていることが、市場の成長に好影響を与えています。これとは別に、より小さく複雑な分子を製造できる新しいPEG化法の開拓など、PEG化技術におけるさまざまな改良が市場成長に弾みをつけています。さらに、コロニー刺激因子(CSF)の安定性と半減期を改善し、治療薬としての効果を高めるためにPEG化が広く採用されていることも、成長を促進する要因となっています。さらに、非タンパク質ベースの薬剤よりもタンパク質ベースの薬剤の採用が増加しており、PEG化によってタンパク質の循環と半減期が増加し、効率が向上していることも市場成長を促進しています。PEG化タンパク質の製品承認数の増加、バイオテクノロジーと分子生物学工学分野の開拓、バイオ医薬品におけるPEG分子の統合と関連する利点、老人人口の増加、製薬業界の規制基準を高めるためのさまざまな政府イニシアチブの実施など、その他の要因も市場のさらなる成長を後押しすると予想されます。
The global PEGylated proteins market size reached US$ 1.3 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 2.8 Billion by 2032, exhibiting a growth rate (CAGR) of 8.87% during 2024-2032. The increasing prevalence of chronic diseases, the widespread product utilization in cancer treatment, and the escalating number of product approvals for PEGylated proteins represent some of the key factors driving the market.
PEGylated proteins are biomolecules that have been modified by covalent conjugation with polyethylene glycol (PEG). It involves the PEGylation technique that improves the pharmacokinetic behavior of the medicine by altering the biological molecule's physical and chemical characteristics, such as its conformation, electrostatic binding, and hydrophobicity. PEGylated proteins are widely used in therapeutic applications, such as vaccines, hormone replacement therapy, genetic disorders, anemia, and blood clotting disorder. It is also used in various drugs for diseases, including kidney disease, multiple sclerosis, hemophilia, and cancers. PEGylated proteins help in the extension of half-life, increasing stability, solubility, and proteolytic protection, reducing renal excretion, immunogenicity, and toxicity, and enhancing the efficacy of drug delivery. Besides this, PEGylated proteins are non-toxic, water-soluble, hydrophilic, non-antigenic, and non-immunogenic.
The rising prevalence of chronic diseases, such as kidney ailments, autoimmune diseases, genetic disorders, hepatitis, and rheumatoid arthritis across the globe is one of the key factors driving the market growth. PEGylated proteins are widely used to treat inflammation, deliver corrective genes to cells, prevent blood clots, deliver growth hormones, and prevent the progression of chronic kidney disease. In line with this, the widespread product utilization in cancer treatment to deliver chemotherapy drugs directly to cancer cells and reduce the side effects on healthy cells is favoring the market growth. Apart from this, various improvements in the PEGylation technology, such as the development of new PEGylation methods that can produce smaller and more complex molecules, are providing an impetus to the market growth. Additionally, the widespread adoption of PEGylation to improve the stability and half-life of colony-stimulating factors (CSFs), making them more effective as therapeutic agents, is acting as another growth-inducing factor. Furthermore, the rising adoption of protein-based drugs over non-protein-based drugs wherein PEGylation increases the circulation and half-life of the proteins, improving its efficiency, is propelling the market growth. Other factors, including the increasing number of product approvals for PEGylated proteins, development in the field of biotechnology and molecular biology engineering, the integration of PEG molecules in biopharmaceuticals and the associated advantages, rising geriatric population, and the implementation of various government initiatives to increase regulatory standards in the pharmaceutical industry, are anticipated drive the market further toward growth.
IMARC Group provides an analysis of the key trends in each segment of the global PEGylated proteins market, along with forecasts at the global, regional, and country level from 2024-2032. Our report has categorized the market based on product, protein type, application, and end user.
Consumables
PEGylation Reagents
PEGylation Kits
Services
A detailed breakup and analysis of the PEGylated proteins market based on the product has also been provided in the report. This includes consumables (PEgylation reagents and PEgylation kits) and services. According to the report, consumables accounted for the largest market share.
Colony Stimulating Factors
Interferons
Erythropoietin
mAbs
Recombinant Factor VII
Others
The report has provided a detailed breakup and analysis of the PEGylated proteins market based on the protein type. This includes colony stimulating factors, interferons, erythropoietin, mAbs, recombinant factor VII and others. According to the report, colony stimulating factors represented the largest segment.
Cancer Treatment
Hepatitis
Chronic Kidney Diseases
Hemophilia
Multiple Sclerosis
Gastrointestinal Disorders
Others
A detailed breakup and analysis of the PEGylated proteins market based on the application has also been provided in the report. This includes cancer treatment, hepatitis, chronic kidney diseases, hemophilia, multiple sclerosis, gastrointestinal disorders, and others. According to the report, cancer treatment represented the largest segment.
Pharmaceutical and Biotechnology Companies
Contract Research Organizations
Academic and Research Institutes
The report has provided a detailed breakup and analysis of the PEGylated proteins market based on the end user. This includes pharmaceutical and biotechnology companies, contract research organizations, and academic and research institutes. According to the report, pharmaceutical and biotechnology companies represented the largest segment.
North America
United States
Canada
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Asia Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
The report has also provided a comprehensive analysis of all the major regional markets that include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America was the largest market for PEGylated proteins. Some of the factors driving the North America PEGylated proteins market included the rising geriatric population, increasing prevalence of chronic diseases, and extensive research and development (R&D).
The report has also provided a comprehensive analysis of the competitive landscape in the global PEGylated proteins market. Detailed profiles of all major companies have also been provided. Some of the companies covered include Abcam plc, Biomatrik Inc., Creative PEGWorks, Iris Biotech GmbH, JenKem Technology USA Inc., Laysan Bio Inc., NOF America Corporation (NOF Corporation), Profacgen, Thermo Fisher Scientific Inc., etc.